Seattle Genetics and Takeda's Adcetris trial meets endpoints in PTCL

1 October 2018
2019_biotech_test_vial_discovery_big

This morning, Japan’s Takeda Pharmaceuticals (TYO: 4502), in partnership with US biotech firm Seattle Genetics (Nasdaq: SGEN), announced that the Phase III ECHELON-2 clinical trial in frontline CD30-expressing peripheral T-cell lymphoma (PTCL) met its primary endpoint.

Notwithstanding what is clearly positive news, Takeda’s shares fell 2.84% to 4,723 yen in the last hour or so of trading in Tokyo, while Seattle Genetics gained 3.9% to $80.14 by late morning trading.

The trial demonstrated a statistically-significant improvement in progression-free survival (PFS) of Adcetris (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus the control arm, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). ECHELON-2 is a global, randomized, double-blind, multicenter trial evaluating Adcetris as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-expressing PTCL.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology